PIK3CA and prostate carcinoma: Al-saffar et al. 24 showed that treatment of prostate cancer cells with the PI3K inhibitor, PI-103 which caused G1 cell cycle arrest and decreased Akt phosphorylation was accompanied by decreased PCho concentration.